天臣医疗: 天臣医疗关于调整公司2022年限制性股票激励计划授予价格及作废处理部分限制性股票的公告

Core Viewpoint - Tianchen Medical has announced adjustments to its 2022 restricted stock incentive plan, including a reduction in the grant price and the cancellation of certain unvested shares due to the departure of two incentive recipients [1][9][11] Summary by Sections Decision Process and Disclosure - The company held a board meeting on May 5, 2022, to approve the draft of the restricted stock incentive plan and related proposals, with independent directors expressing their agreement [2][3] - The company disclosed the plan on the Shanghai Stock Exchange on May 6, 2022, and conducted a public notice period for the incentive recipients from May 9 to May 18, 2022, with no objections received [3][4] Adjustments and Results - The adjusted grant price for the restricted stock is set at RMB 10.55 per share, down from RMB 12.05 per share, following a calculation that accounts for cash dividends distributed to shareholders [8][9] - The company will cancel 4,400 shares of restricted stock that were granted but not vested due to the departure of two incentive recipients [9][11] Impact on the Company - The adjustments to the grant price and the cancellation of shares are not expected to have a material impact on the company's financial status or operational results, nor will they affect the stability of the core team or the implementation of the incentive plan [9][11] Opinions from Committees - The Board's Compensation and Assessment Committee supports the adjustments, stating they comply with relevant laws and regulations, and do not harm the interests of the company or its shareholders [10][11] Legal Opinions - Legal counsel confirms that the adjustments and cancellations have received necessary approvals and comply with applicable regulations, ensuring no adverse effects on the company's financial health or incentive plan execution [11]